BioCorRx Awarded NIDA Grant of Approximately $5.7 Million for BICX102, a Sustained Release Naltrexone Implant for the Treatment of Opioid Use Disorder
January 22, 2019 07:30 ET
|
BioCorRx Inc
ANAHEIM, CA, Jan. 22, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use...
BioCorRx Provides BICX102 Grant Update
October 02, 2018 07:51 ET
|
BioCorRx Inc
ANAHEIM, CA, Oct. 02, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use...
BioCorRx Provides Business Update for the First Quarter of 2018
May 21, 2018 07:30 ET
|
BioCorRx, Inc.
ANAHEIM, CA, May 21, 2018 (GLOBE NEWSWIRE) -- BioCorRx, Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, today provided...
BioCorRx Comments on President Donald J. Trump’s Initiative to Stop Opioid Abuse
March 20, 2018 10:40 ET
|
BioCorRx Inc
ANAHEIM, CA, March 20, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions,...
Dr. Joseph DeSanto and BioCorRx Recovery Program Participant Appear on the TV Show, The Doctors
February 15, 2018 08:00 ET
|
BioCorRx Inc
ANAHEIM, CA, Feb. 15, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today...
BioCorRx Announces Results of Pre-IND meeting with FDA for Sustained Release Naltrexone Implant, BICX102
February 12, 2018 09:23 ET
|
BioCorRx Inc
505(b)(2) application plan acceptable per FDA Application will seek dual indications for opioid and alcohol use disorders ANAHEIM, CA, Feb. 12, 2018 (GLOBE NEWSWIRE) -- BioCorRx...
BioCorRx Extends Service Agreement with Dr. Balbir S. Brar as VP of Drug Development Following Pre-IND Meeting with the U.S. FDA
February 08, 2018 07:30 ET
|
BioCorRx, Inc.
ANAHEIM, CA, Feb. 08, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTC: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today...
BioCorRx Completes Pre-IND Meeting with FDA; Reports Company to Move Forward with BICX102
January 26, 2018 07:30 ET
|
BioCorRx, Inc.
ANAHEIM, CA , Jan. 26, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today...